EpiVax out-licenses COVID-19 vaccine candidate

PROVIDENCE – EpiVax Inc. has out-licensed its COVID-19 vaccine candidate to EpiVax Therapeutics, based in New York. EVT, a venture-backed company that was previously named EpiVax Oncology that is a spin-out of EpiVax Inc., will seek to raise an additional $3 million for the new vaccine program and has recently reorganized its executive team in preparation…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

If you have already logged in and are still seeing this message, please refresh the page as your browser is caching the old content.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.